Riskpilot← Back to searchSign inGet full accessBonnier Pharma Insights AB
ABDissolvedOrg 5590198130Computer programming activities · NACE 6201Est. 20156 employees
Revenue 2020
SEK 7M
+19% vs 2019
EBITDA margin
6.6%
+45% vs 2019
Equity ratio
27.6%
Financial strength
Net profit 2020
SEK 607K
+306% vs 2019
| Revenue | SEK 7M | +19% |
| EBITDA | SEK 465K | +45% |
| Net profit | SEK 607K | +306% |
| Total assets | SEK 4,8M | +28% |
| Equity | SEK 1,3M | +85% |
| Employees | 6 | — |
Legal name
Bonnier Pharma Insights AB
Org number
5590198130
Legal form
Aktiebolag
NACE code
6201 · Computer programming activities
Founded
6 juli 2015
Share capital
SEK 0
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Company purpose
Bolaget skall leverera tjänster och statistik till läkemedelsindustrin och även andra branscher med behov av statistikrelaterade lösningar i form av weblösningar, personaluthyrning (konsult) men också skapa avancerade lösningar med statistik i grunden, samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 4 126 | 6 332 | 5 588 | 5 915 | 7 024 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −723 | 312 | −431 | 320 | 465 |
| Depreciation & amort. | −838 | −838 | −838 | −838 | −558 |
| EBIT | −1 561 | −526 | −1 269 | −518 | −93 |
| Net financials | −15 | −8 | −1 | −1 | — |
| Profit before tax | −1 532 | −533 | −1 270 | −519 | −93 |
| Tax | −0 | −0 | −0 | 225 | 700 |
| Net profit | −1 532 | −533 | −1 270 | −294 | 607 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 6 880 | 6 098 | 3 928 | 3 754 | 4 798 |
| Equity | 2 813 | 2 280 | 1 011 | 717 | 1 324 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 067 | 3 818 | 2 917 | 3 037 | 3 474 |
| Total debt | 4 067 | 3 818 | 2 917 | 3 037 | 3 474 |
EBITDA margin
6.6%
This company
15.8%
Market median
-58% vs market
20162020
Equity ratio
27.6%
This company
38.2%
Market median
-28% vs market
20162020
Return on equity
45.8%
This company
18.4%
Market median
+149% vs market
20162020
Net profit margin
8.6%
This company
8.1%
Market median
+6% vs market
20162020
Asset turnover
1.46×
This company
1.12×
Market median
+30% vs market
20162020
Debt / equity
2.62×
This company
0.62×
Market median
-323% vs market
20162020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
JE Chief Auditor | Chief Auditor | 2021 – 2022 |
FB Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bonnier Pharma Insights AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jeanette Elisabeth Cranning | Chief Auditor | 0 companies |
| Fredrik Bengt Jarl Andersson | Chief Executive Officer | 0 companies |
| Karmo Kaas-Lutsberg | Chairman | 0 companies |
| Nils Arne Vilhelm Thernfrid | Board of Directors | 0 companies |